ストックスクリーナーアプリを入手
0.9844
0.93%
-0.0092
アフターアワーズ：
.99
0.0056
+0.57%
前日終値:
$0.9936
開ける：
$0.9912
24時間の取引高:
1.50M
Relative Volume:
0.29
時価総額：
$241.80M
収益：
$116.33M
当期純損益:
$-209.25M
株価収益率:
-0.4643
EPS:
-2.12
ネットキャッシュフロー:
$-135.49M
1週間 パフォーマンス:
-5.35%
1か月 パフォーマンス:
+15.84%
6か月 パフォーマンス:
-55.25%
1年 パフォーマンス:
-55.66%
1日の値動き範囲:
$0.9842
$1.03
1週間の範囲:
$0.9842
$1.095
52週間の値動き範囲:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
名前
Esperion Therapeutics Inc
セクター
電話
734-887-3903
住所
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
ESPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
0.9844 | 241.80M | 116.33M | -209.25M | -135.49M | -2.12 |
|
RGC
Regencell Bioscience Holdings Ltd
|
17.04 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
155.95 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.37 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.46 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.76 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-18 | 開始されました | Goldman | Neutral |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-06-20 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-01 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | アップグレード | BofA Securities | Underperform → Buy |
| 2023-03-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-03-16 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 再開されました | BofA Securities | Neutral |
| 2023-02-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-02-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-19 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-12 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-09 | ダウングレード | Goldman | Neutral → Sell |
| 2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-10 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Underweight |
| 2020-08-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 再開されました | BofA/Merrill | Buy |
| 2020-03-17 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-24 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-16 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-29 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | アップグレード | Goldman | Sell → Neutral |
| 2019-03-13 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 繰り返されました | Needham | Strong Buy |
| 2018-12-13 | 開始されました | Goldman | Sell |
| 2018-10-29 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 開始されました | BTIG Research | Buy |
| 2018-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2018-07-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-05-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
すべてを表示
Esperion Therapeutics Inc (ESPR) 最新ニュース
ESPR: HC Wainwright Reiterates Buy Rating with $16 Price Target - GuruFocus
Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha
Cantor Fitzgerald reiterates Esperion stock rating, sees growth potential By Investing.com - Investing.com Canada
ESPR Leadership to Discuss Future Strategies in Upcoming Conference Call | ESPR Stock News - GuruFocus
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Traders Purchase High Volume of Esperion Therapeutics Call Options (NASDAQ:ESPR) - Defense World
Transcript : Esperion Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
Research Analysts Offer Predictions for ESPR Q2 Earnings - Defense World
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018ESPR - ACCESS Newswire
Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report? - Yahoo Finance
Esperion at Jefferies Global Healthcare: Expanding Opportunities By Investing.com - Investing.com South Africa
Esperion at Jefferies Global Healthcare: Expanding Opportunities - Investing.com Australia
ProShare Advisors LLC Boosts Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Millennium Management LLC Has $1.83 Million Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Esperion settles patent case with Hetero USA over cholesterol drug By Investing.com - Investing.com South Africa
Esperion settles patent case with Hetero USA over cholesterol drug - Investing.com
Esperion reaches settlement agreement with Hetero USA, affiliates - TipRanks
Esperion (ESPR) Reaches Settlement to Protect NEXLETOL Patents | ESPR Stock News - GuruFocus
Esperion Reaches Settlement Agreement with Second ANDA - GlobeNewswire
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - The Manila Times
Esperion Secures 15-Year Market Exclusivity for NEXLETOL in Major Patent Victory - Stock Titan
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Bank of America Corp DE - Defense World
Deutsche Bank AG Sells 1,393,852 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Zacks Research Has Pessimistic Outlook of ESPR Q2 Earnings - Defense World
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Lifted by Nuveen Asset Management LLC - Defense World
Zacks Research Has Positive Outlook of ESPR FY2027 Earnings - Defense World
BNP Paribas Financial Markets Has $337,000 Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
D. E. Shaw & Co. Inc. Grows Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Northern Trust Corp Buys 65,662 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Esperion Therapeutics discovers new ATP citrate lyase inhibitors - BioWorld MedTech
Esperion to Participate in Upcoming June Investor Conferences - GlobeNewswire
Esperion at H.C. Wainwright Conference: Strategic Growth and Future Plans - Investing.com
Esperion to Present Latest Cardiovascular Drug Developments at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.25 Average Target Price from Brokerages - Defense World
Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival - insights.citeline.com
Raymond James Financial Inc. Invests $98,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - Defense World
Esperion Therapeutics, Micro Labs Settle Generic Nexletol Patent Dispute - marketscreener.com
Esperion reaches settlement agreement with Micro Labs - TipRanks
Esperion Settles Patent Litigation With Micro Labs For Generic Nexletol - Nasdaq
Esperion (ESPR) Reaches Settlement with Micro Labs Over Patent Dispute | ESPR Stock News - GuruFocus
Esperion Reaches Settlement Agreement With ANDA Filer Not To Market Generic Version Of Nexletol - marketscreener.com
Esperion Settles Patent Litigation with Micro Labs Regarding NEXLETOL Generic Marketing Rights - Nasdaq
Esperion Reaches Settlement Agreement with ANDA Filer Not - GlobeNewswire
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - Stock Titan
Cantor Fitzgerald Has Negative View of ESPR FY2025 Earnings - Defense World
Needham & Company LLC Cuts Esperion Therapeutics (NASDAQ:ESPR) Price Target to $4.00 - Defense World
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - The Globe and Mail
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines - Yahoo Finance
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference - GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Esperion at The Citizens JMP Life Sciences Conference: Strategic Growth Insights - Investing.com India
Esperion Therapeutics Inc (ESPR) 財務データ
収益
当期純利益
現金流量
EPS
Esperion Therapeutics Inc (ESPR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Koenig Sheldon L. | President and CEO |
Jun 17 '25 |
Sale |
1.11 |
30,474 |
33,796 |
1,541,488 |
| Halladay Benjamin | Chief Financial Officer |
Jun 17 '25 |
Sale |
1.15 |
7,229 |
8,328 |
474,473 |
0.07%
0.22%
大文字化:
|
ボリューム (24 時間):